AZD 9819Alternative Names: AZD9819
Latest Information Update: 01 Aug 2011
At a glance
- Originator AstraZeneca
- Class Antiasthmatics
- Mechanism of Action Leucocyte elastase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 28 Jul 2011 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
- 31 Aug 2010 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation)